## KURZPROTOKOLL TRANSATRA

Öffentlicher Titel

Phase I/II Studie zu Dosisfindung und Wirksamkeit von Tranylcypromine bei Patienten

mit nicht-APL AML

Wissenschaftl. Titel

Phase I/II study of sensitization of non-M3 acute myeloid leukemia (AML) blasts to all-trans retinoic acid (ATRA) by epigenetic treatment with tranylcypromine (TCP), an

inhibitor of the histone lysine demethylase 1 (LSD1)

**Kurztitel** 

**TRANSATRA** 

**Studienart** 

multizentrisch, offen/unverblindet, einarmig, Investigator Initiated Trial (IIT)

Studienphase

Phase I/II

**Erkrankung** 

Blut: Myeloische Neoplasien/Dysplasien: Myelodysplastische Syndrome (MDS)

Blut: Akute myeloische Leukämie (AML): Neu diagnostiziert / de novo

Blut: Akute myeloische Leukämie (AML): Rezidiviert/refraktär

Einschlusskriterien

- Patients >18 years (no upper age limit)
- AML (WHO) or intermediate or higher risk MDS/ Chronic Myelomonocytic Leukemia (CMML) (IPSS-R >3.0)
- No standard treatment available (comorbidities, higher age, refractoriness to standard or salvage chemotherapy and allografting, azanucleosides failure\*)
- Patients with < 30.000 leukocytes/µ</li>
- Eastern Cooperative Oncology Group (ECOG) 0,1,2
- Written informed consent obtained according to international guidelines and local laws
- Ability to understand the nature of the trial and the trial related procedures and to comply with them.

## Ausschlusskriterien

- Acute promyelocytic leukemia (APL, French-American-British classification system (FAB) M3)
- Eligibility for standard induction or consolidation chemotherapy, immediate allografting, or a hypomethylating agent
- AML with central nervous system (CNS) involvement
- AraC treatment within one month prior to registratio
- Prior exposure to histone deacetylase inhibitors, including sodium valproate within one month prior to registration
- Stem cell transplant patient with graft-versus-host disease (GvHD) or under systemic immunosuppression
- Previous gastrointestinal surgery that might interfere with drug absorption
- Pheochromocytom
- Carcinoid tumor
- Confirmed or suspected cerebrovascular disease
- Vascular malformations including aneurysm
- Severe renal insufficiency
- Severe or poorly controlled hypertension
- Severe cardiovascular disease;
- Hepatic insufficiency/liver disease;
- Porphyria
- Diabetes insipidus;
- History or presence of malignant hyperthermia
- Known psychiatric disorders
- Known allergy against soy beans or peanuts

## KURZPROTOKOLL TRANSATRA

- Known hypersensitivity to or intolerance of one of the trial drugs or its constituents (e.g. lactose, corn starch, indigocarmine (TCP), corn starch (AraC), other retinoids (ATRA))
- Simultaneous intake of the prohibited medication, incl. linezolid, that is likely to cause interactions (see detailed list study protocol)
- Patients who refuse to follow study-specific dietary guidelines
- Known or persistent abuse of medication, drugs or alcohol
- Current or planned pregnancy, nursing period
- Failure to use safe methods of contraception
- Inclusion Criteria: Patients eligible for inclusion in this trial must meet all of the following criteria: Patients >18 years (no upper age limit); AML (WHO) or intermediate or higher risk MDS/ Chronic Myelomonocytic Leukemia (CMML) (IPSS-R >3.0); No standard treatment available (comorbidities, higher age, refractoriness to standard or salvage chemotherapy and allografting, azanucleosides failure\*); Patients with < 30.000 leukocytes/µl; Eastern Cooperative Oncology Group (ECOG) 0,1,2; Written informed consent obtained according to international guidelines and local laws; Ability to understand the nature of the trial and the trial related procedures and to comply with them. Azanucleosides failure is defined as 1) no response after at least three (AML) or six (MDS) cycles of azacitidine or decitabine, 2) disease progression under treatment or 3) grade 3-4 non-hematologic toxicity. Exclusion Criteria: Patients eligible for this trial must not meet any of the following criteria: Acute promyelocytic leukemia (APL, French-American-British classification system (FAB) M3); Eligibility for standard induction or consolidation chemotherapy, immediate allografting, or a hypomethylating agent; AML with central nervous system (CNS) involvement; AraC treatment within one month prior to registration; Prior exposure to histone deacetylase inhibitors, including sodium valproate within one month prior to registration; Stem cell transplant patient with graft-versus-host disease (GvHD) or under systemic immunosuppression; Previous gastrointestinal surgery that might interfere with drug absorption; Pheochromocytoma; Carcinoid tumor; Confirmed or suspected cerebrovascular disease; Vascular malformations including aneurysm; Severe renal insufficiency; Severe or poorly controlled hypertension; Severe cardiovascular disease: Hepatic insufficiency/liver disease: Porphyria: Diabetes insipidus; History or presence of malignant hyperthermia; Known psychiatric disorders; Known allergy against soy beans or peanuts; Known hypersensitivity to or intolerance of one of the trial drugs or its constituents (e.g. lactose, corn starch, indigocarmine (TCP), corn starch (AraC), other retinoids (ATRA)); Simultaneous intake of the prohibited medication, incl. linezolid, that is likely to cause interactions (see detailed list study protocol); Patients who refuse to follow study-specific dietary auidelines: Known or persistent abuse of medication, drugs or alcohol: Current or planned pregnancy, nursing period; Failure to use safe methods of contraception; Simultaneous participation in other interventional trials which could interfere with this trial and/or participation before the end of a required restriction period; Participation in a clinical trial within the last 30 days before the start of this trial Persons who are in a relationship of dependence/employment with the sponsor or the investigator;
- Participation in a clinical trial within the last 30 days before the start of this trial
- Persons who are in a relationship of dependence/employment with the sponsor or the investigator

Alter 18 Jahre und älter

Fallzahl 60

SponsorUniversitätsklinikum FreiburgFördererUniversitätsklinikum FreiburgRegistrierung in anderenClinicalTrials.gov NCT02717884StudienregisternEudraCT 2014-001479-30